Silexion Therapeutics (NASDAQ: SLXN) announced promising preclinical results for SIL-204, its second-generation siRNA therapy targeting KRAS-mutated cancers. The data show SIL-204 acts synergistically with standard chemotherapy agents like 5-fluorouracil, irinotecan, and gemcitabine, significantly reducing cancer cell confluence in KRAS G12D mutated pancreatic cancer cell lines. This builds on earlier successes with Silexion’s first-generation product, LODER™, which improved overall survival in Phase 2 trials.

These findings are particularly important because pancreatic cancer, especially with the prevalent KRAS G12D mutation, is notoriously difficult to treat and has a high mortality rate. The demonstrated synergy between SIL-204 and existing chemotherapy regimens suggests the potential for improved treatment efficacy and patient outcomes, addressing a critical unmet need. The positive results with SIL-204 also expand Silexion’s pipeline beyond LODER™ and broaden its potential impact across multiple KRAS-mutated cancers beyond pancreatic cancer.

Preclinical studies showed a statistically significant reduction in cancer cell confluence after just three days of combined treatment with SIL-204 and either the 5-fluorouracil/irinotecan combination or gemcitabine alone, compared to chemotherapy alone (p < 0.0005). Silexion is preparing to initiate toxicology studies with SIL-204 in the coming months, with plans to advance it to Phase 2/3 clinical trials in the first half of 2026, initially focusing on locally advanced pancreatic cancer. Concurrent preclinical studies are also planned for SIL-204 in colorectal cancer models. These developments position Silexion to potentially change the treatment paradigm for KRAS-driven cancers. The upcoming clinical trials for SIL-204 will be crucial in validating these preclinical findings and determining the true clinical benefit for patients. The parallel investigation in colorectal cancer further expands the potential scope of SIL-204’s therapeutic impact. The positive preclinical results combined with planned clinical development suggest a promising future for Silexion and provide a potential new avenue of treatment for patients facing these challenging cancers.

Source link: https://www.globenewswire.com/news-release/2025/01/15/3010424/0/en/Silexion-Therapeutics-Announces-Additional-Promising-Preclinical-Data-for-SIL-204-Demonstrating-Impressive-Synergy-with-First-Line-Pancreatic-Cancer-Chemotherapies.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.